Search results for "Virus diseases"

showing 10 items of 953 documents

Second European Multi-Disciplinary Conference of National Strategies for Chlamydia Trachomatis and Human Papillomavirus (NSCP Conference) in Berlin, …

2013

There is a need for updated guidance on detection, management and surveillance of sexually transmitted infections (STIs). Chlamydia, gonorrhoea and syphilis reporting needs to be mandatory in more European countries to aid collection of data. More widespread Chlamydia screening is needed in many countries as this is the only way to reduce complications. The role of Human Papillomavirus (HPV) screening in a situation where the prevalence of HPV infection has dropped significantly was also discussed in the context of the high cost of screening, the need for a relatively complex infrastructure, particularly in developing countries, and falling vaccination costs. An integrated HPV vaccination …

PharmacologyGynecologymedicine.medical_specialtyChlamydiabusiness.industryImmunologyHPV infectionvirus diseasesDeveloping countryContext (language use)medicine.diseasemedicine.disease_causefemale genital diseases and pregnancy complicationsGenital wartsVaccinationEnvironmental healthmedicineImmunology and AllergybusinessChlamydia trachomatisMass screeningInternational Journal of Immunopathology and Pharmacology
researchProduct

Molecular surveillance of norovirus, 2005–16 : an epidemiological analysis of data collected from the NoroNet network

2018

BACKGROUND: The development of a vaccine for norovirus requires a detailed understanding of global genetic diversity of noroviruses. We analysed their epidemiology and diversity using surveillance data from the NoroNet network.METHODS: We included genetic sequences of norovirus specimens obtained from outbreak investigations and sporadic gastroenteritis cases between 2005 and 2016 in Europe, Asia, Oceania, and Africa. We genotyped norovirus sequences and analysed sequences that overlapped at open reading frame (ORF) 1 and ORF2. Additionally, we assessed the sampling date and country of origin of the first reported sequence to assess when and where novel drift variants originated.FINDINGS: W…

0301 basic medicineDatabases FactualvirusesVARIANTSmedicine.disease_causeDisease OutbreaksEMERGENCEfluids and secretions[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesEpidemiologyGenotypeTOOLmedia_commonCaliciviridae InfectionsMolecular Epidemiologyvirus diseasesrespiratory system3. Good healthGastroenteritis[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInfectious DiseasesGeography[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyRNA Viral[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyOUTBREAKSmedicine.medical_specialtyEUROPEGenotypeTRANSMISSIONVIRUSES[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology03 medical and health sciencesSDG 3 - Good Health and Well-beingGenetic driftEnvironmental healthmedicinemedia_common.cataloged_instanceHumansEuropean unionRetrospective StudiesGenetic diversityMolecular epidemiologyNorovirusOutbreakGenetic Variation[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyADULTSdigestive system diseasesEVOLUTION030104 developmental biology3121 General medicine internal medicine and other clinical medicineNorovirushuman activities
researchProduct

Treatment options in HBV.

2005

The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to conclude that in patients with HBeAg positive chronic hepatitis, standard IFN therapy significantly improves clearance of HBeAg (number needed to treat [NNT] = 4), loss of HBV-DNA (NNT = 4) and clearance of HBsAg (NNT = 18). HBeAg positive patients with normal or slightly raised ALT should be treated only if there is histological evidence of progressive disease. In patients with HBeAg negative chronic hepatitis, less than 20% of subjects who have achieved an end-of-treatment virological response after a course of standard IFN maintain a sustained virological response in the long-term. IFN tre…

Hepatitis B virusHBsAgmedicine.medical_specialtyAdefovirmedicine.disease_causeAntiviral AgentsGastroenterologyHepatitis B AntigensLiver diseaseInternal medicineAdefovirHumansMedicineHepatitis B virusHepatologybusiness.industryvirus diseasesLamivudineHIVHepatitis Bmedicine.diseaseHepatitis Bdigestive system diseasesTreatmentTreatment OutcomeHBeAgLamivudineDNA ViralImmunologyNumber needed to treatInterferonbusinessLiver diseasemedicine.drug
researchProduct

Local adaptation in populations of Mycobacterium tuberculosis endemic to the Indian Ocean Rim

2021

24 páginas, 3 figuras, 1 tabla. The sequence data generated by this study has been deposited on SRA (https://www.ncbi.nlm.nih.gov/sra) under the accession number PRJNA670836. Extended data is available here: https://github.com/fmenardo/MTBC_L1_L3. DOI: https://doi.org/10.5281/zenodo.4609804 (Menardo, 2021).

0301 basic medicineMycobacterium tuberculosis / patogenicidadeTuberculosisGenotypevirusesLineage (evolution)030106 microbiologyLocus (genetics)adaptationBiologyGenomeGeneral Biochemistry Genetics and Molecular BiologyMycobacterium tuberculosis03 medical and health sciencesAdapta??oGenoma BacterianomedicineHumansOceano ?ndico / epidemiologiaGeneral Pharmacology Toxicology and PharmaceuticsAdaptationIndian OceanLocal adaptationGenetic diversityGeneral Immunology and Microbiologyvirus diseasesTuberculose / patologiaGeneral MedicineArticlesMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseasedigestive system diseases3. Good health030104 developmental biologyMycobacterium tuberculosis complexEvolutionary biologycoevolutionLinhagemCoevolutionResearch ArticleF1000Research
researchProduct

Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group

2019

Abstract Hepatitis C virus (HCV) remains a significant public health problem and is one of the major causes of chronic liver disease worldwide. In recent years many new tools to facilitate widespread HCV screening and new therapeutic options with excellent efficacy and tolerability profiles and cost lowering policies have become available. To fully utilise these new tools, the link between local and specialist centres for the management of HCV infection must be reinforced. In order to GAIN further insight into these aspects, with a particular focus on the Italian scenario, a group of experts met to discuss relevant aspects and open issues on chronic HCV. As a summary of that meeting, the fo…

Liver Cirrhosismedicine.medical_specialtyHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeAntiviral Agents03 medical and health sciences0302 clinical medicineLinkage to careHumansMass ScreeningMedicineEradication; Hepatitis C virus; Linkage to careIntensive care medicineSocieties MedicalEradicationHepatologybusiness.industryHepatitis C virusAdvanced cirrhosisPublic healthManaged Care ProgramsGastroenterologyvirus diseasesFocus Groupsmedicine.diseaseHepatitis CFocus groupdigestive system diseasesItalyTolerability030220 oncology & carcinogenesisHCV030211 gastroenterology & hepatologybusinessHepatitis C viruHealthcare providers
researchProduct

Cytoprotective effect of resveratrol diastereomers in CHO-K1 cells exposed to beauvericin

2015

Beauvericin (BEA) causes cytotoxicity, lipid peroxidation and reactive oxygen species in CHO-K1 cells. Resveratrol (RSV) is a polyphenol with multiple biological properties, including antioxidant effects. RSV has two forms: trans and cis. The aims of this study were to determine the cytoprotective effect of trans-RSV and diastereomers mixtures (50:50 trans/cis-RSV and 70:30 trans/cis-RSV) incubated alone and in combination with BEA in ovarian (CHO-K1) cells. The results demonstrated that cell viability increases (from 9% to 77%) when they were exposed to low concentration of RSV. Moreover, when the cells were pre-treated with RSV and then exposed to BEA, a cytoprotective effect (from 25% to…

Antioxidantvirusesmedicine.medical_treatmentCHO CellsResveratrolToxicologymedicine.disease_causeLipid peroxidationchemistry.chemical_compoundCricetulusCricetinaeDepsipeptidesStilbenesmedicineAnimalsViability assayCytotoxicitychemistry.chemical_classificationReactive oxygen speciesChemistryvirus diseasesGeneral Medicinerespiratory systemMolecular biologyBeauvericinBiochemistryCytoprotectionResveratrolLipid PeroxidationReactive Oxygen SpeciesOxidative stressFood ScienceFood and Chemical Toxicology
researchProduct

HCV genotype 5: an orphan virus

2013

HCV genotype 5 (HCV-5) is the least known HCV genotype. It is found mainly in South Africa and in restricted areas of Belgium, Spain, France, Syria and Greece. Sporadic cases are reported worldwide. The main modes of transmission are blood transfusion and iatrogenic causes. Little is known about its origin, but various studies have elucidated its spread worldwide. In endemic areas, patients infected with HCV-5 are on average older and have a higher viral load and more advanced fibrosis than those infected with non-HCV-5 genotypes. The current standard of care for HCV-5 chronic infection is 48 weeks of dual therapy with pegylated interferon plus ribavirin. ‘Favourable’ Il28B polymorphisms a…

Blood transfusionGenotypemedicine.medical_treatmentHepacivirusAntiviral Agentschemistry.chemical_compoundPegylated interferonGenotypemedicinePrevalenceHumansPharmacology (medical)PharmacologyTransmission (medicine)business.industryRibavirinvirus diseasesHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseasesChronic infectionInfectious DiseasesTreatment OutcomechemistryImmunologyHost-Pathogen InteractionsbusinessViral loadmedicine.drug
researchProduct

Detection of Hepatitis B Virus DNA in the Liver of Children with Chronic Hepatitis B by In Situ Hybridization and Its Relation to Other Viral Markers

1992

The aim of the study was to detect hepatitis B virus (HBV) DNA by in situ hybridization (ISH) with a 35S-labeled radioactive probe in frozen liver biopsy tissue sections of 63 hepatitis B virus surface antigen (HBsAg)-positive children. The results were compared to other markers of viral replication. HBV DNA was detected in 48 children. Of the 15 negative cases, four had hepatitis B envelope antigen (HBeAg), 10 anti-HBe, and one neither HBeAg nor anti-HBe. Free HBV DNA in serum and liver was positive in one patient. Forty of the positive children were HBeAg- and six anti-HBe-positive; two were negative for both. Of 45 36 had HBV DNA in serum. In 38 of 47 HBV DNA and in 31 of 42 HBcAg could …

Genetic MarkersMaleHepatitis B virusHBsAgAdolescentHepatitis B virus DNA polymerasemedicine.disease_causemedicineHumansChildHepatitis B virusbiologymedicine.diagnostic_testGastroenterologyInfantNucleic Acid Hybridizationvirus diseasesHepatitis BHepatitis Bbiology.organism_classificationmedicine.diseaseHepatitis B Core AntigensVirologydigestive system diseasesBlotting SouthernHBcAgLiverHepadnaviridaeHBeAgChild PreschoolLiver biopsyChronic DiseaseDNA ViralPediatrics Perinatology and Child HealthFemaleJournal of Pediatric Gastroenterology and Nutrition
researchProduct

Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition.

2011

The combined pharmacological approach to the treatment of HIV infection, known as highly active antiretroviral therapy (HAART), has dramatically reduced AIDS-related morbidity and mortality. However, its use has been associated with serious adverse reactions, of which those resulting from mitochondrial dysfunction are particularly widespread. Nucleos(t)ide-reverse transcriptase inhibitors (NRTIs) have long been considered the main source of HAART-related mitochondrial toxicity due to their ability to inhibit Pol-γ, the DNA polymerase responsible for the synthesis of mitochondrial DNA. Nevertheless, accumulating evidence points to a more complex relationship between these organelles and NRTI…

Mitochondrial DNAMitochondrial DiseasesNucleic Acid Synthesis InhibitorDNA polymeraseAnti-HIV Agentsmedicine.medical_treatmentDNA-Directed DNA PolymeraseMitochondrionPharmacologyToxicologyAntiretroviral Therapy Highly ActivemedicineAnimalsHumansNucleic Acid Synthesis InhibitorsPharmacologyProteasebiologyvirus diseasesmedicine.diseaseReverse transcriptaseDNA Polymerase gammaMitochondriaMitochondrial toxicityToxicitybiology.proteinReverse Transcriptase InhibitorsTrends in pharmacological sciences
researchProduct

Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induct…

2002

High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough w…

AdultMaleCombination therapyAdolescentHepacivirusAlpha interferonViremiaEnzyme-Linked Immunosorbent AssayHepacivirusPharmacologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialInterferonlawVirologyRibavirinHumansMedicineViremiaAgedAntiviral AgentHepatologybiologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessmedicine.drugHuman
researchProduct